Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
93.30
-2.70 (-2.81%)
Streaming Delayed Price
Updated: 11:03 AM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biontech Se ADR
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
61
62
Next >
Overview Of Value Stocks In The Healthcare Sector
April 17, 2023
Via
Benzinga
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
April 12, 2023
Via
Benzinga
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
April 11, 2023
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a...
Via
Benzinga
What 12 Analyst Ratings Have To Say About BioNTech
April 10, 2023
Via
Benzinga
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
April 08, 2023
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...
Via
Talk Markets
A Look Into BioNTech Inc's Price Over Earnings
April 03, 2023
Via
Benzinga
Bear of the Day: BioNTech
March 28, 2023
BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines.
Via
Talk Markets
These Analysts Revise Price Targets On BioNTech After Q4 Results
March 28, 2023
BioNTech SE (NASDAQ: BNTX) reported a decline in sales for its fourth quarter.
Via
Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
April 04, 2023
Via
Benzinga
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
April 04, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
April 03, 2023
From
BioNTech SE
Via
GlobeNewswire
Why Shares of BioNTech Slumped Monday
March 27, 2023
The company released fourth-quarter earnings.
Via
The Motley Fool
BioNTech Earnings Preview
March 24, 2023
Via
Benzinga
4 Analysts Have This to Say About BioNTech
March 23, 2023
Via
Benzinga
Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review
March 31, 2023
The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica.
Via
Investor's Business Daily
NVIDIA To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Tuesday
March 28, 2023
B of A Securities cut the price target for Fox Corporation (NASDAQ: FOXA) from $42 to $34. B of A Securities analyst Jessica Reif Ehrlich downgraded the stock from Buy to Neutral. Fox shares fell 1.8%...
Via
Benzinga
BioNTech Announces New ADS Repurchase Program
March 28, 2023
From
BioNTech SE
Via
GlobeNewswire
Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories
March 27, 2023
Benzinga
Via
Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
March 27, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
BioNTech Is Ripe For A Rebound In 2023
March 27, 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion
March 27, 2023
For the year, BioNTech said it expects about $5.4 billion in sales of its Covid shot.
Via
Investor's Business Daily
Why BioNTech Shares Are Trading Lower Today
March 27, 2023
BioNTech SE (NASDAQ: BNTX) shares are falling in the premarket session today after the company reported Q4 earnings and expected lower annual revenue from the Covid-19 vaccine.
Via
Benzinga
Earnings Scheduled For March 27, 2023
March 27, 2023
Companies Reporting Before The Bell • Viomi Technology Co (NASDAQ:VIOT) is likely to report earnings for its fourth quarter. • Vislink Technologies (NASDAQ:VISL) is projected to report earnings for its...
Via
Benzinga
US Stocks Poised To Start New Trading Week Higher On Hopes Of Resolving Banking Crisis: Analyst Warns 'No News Would Be Good News'
March 27, 2023
The recent positive momentum seen in the market could carry over into the new week, as indicated by the index futures, which were holding up early Monday.
Via
Benzinga
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
March 27, 2023
From
BioNTech SE
Via
GlobeNewswire
Could CRISPR Therapeutics Become the Next Moderna?
March 27, 2023
Both companies use cutting-edge technology.
Via
The Motley Fool
Carnival, BioNTech And 3 Stocks To Watch Heading Into Monday
March 27, 2023
With US futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Investor Fear Increases Amid Recent Bank Concerns
March 27, 2023
The CNN Money Fear and Greed index showed some increase in the fear level among U.S. investors. US stocks closed higher on Friday following a volatile trading session. All the major indices recorded...
Via
Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
March 23, 2023
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move.
Via
InvestorPlace
China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine
March 22, 2023
Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's (OTC: CSPCY) messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization.
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
61
62
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.